WEE1 and atherosclerosis: It is worth mentioning that MK1775 showed the gastrointestinal reaction side‐effect in its clinical trials treating cancers.[31] Therefore, it is suggested to develop new small‐molecule inhibitors targeting the interaction between WEE1 and p65 to treat atherosclerosis, which may avoid the side effects of the classic anti‐cancer inhibitors of WEE1 kinase.